Welcome to our dedicated page for Biophytis Sa SEC filings (Ticker: BPTSY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biophytis SA filings document its foreign private issuer reporting for an ADR linked to a clinical-stage biotechnology company focused on age-related diseases. The company files Form 6-K reports that furnish press releases, interim financial reporting, meeting results, and other information distributed by the French issuer.
The filing record addresses BIO101 program disclosures, sarcopenia and obesity development updates, strategic and co-development agreements, capital increases, warrants, convertible debt repayment, bond financing amendments, and shareholder governance matters. These disclosures also show how the company reports financing activity and program spending alongside its Euronext Growth Paris ordinary-share listing and OTC ADS program.
Biophytis S.A. has amended its straight bond financing facility with Hexagon Capital Fund, converting it into a revolving structure capped at 2,000 bonds outstanding and reducing the annual interest rate from 12% to 10%.
The facility is described as a €2 million line, supporting Biophytis’ plan to finance a joint venture in Hong Kong and the Phase 3 study in sarcopenia, as well as preparation of its obesity program. Since February 2026, 800 bonds with a nominal value of €800,000 have been issued, largely repaid through share issuances and offset receivables, leaving drawing capacity of €1,700,000 under the bond facility.
Biophytis SA, a clinical-stage biotechnology company, has postponed publication of its annual financial statements for the year ended December 31, 2025. The company says work on a €2.015 million refinancing transaction required significant management and staff attention, delaying completion of its closing process and auditor review.
As a result, Biophytis will miss the statutory April 30, 2026 deadline for publishing its 2025 accounts, but indicates it is working to finalize and release the financial statements by the end of May 2026.
Biophytis SA, a clinical-stage biotech focused on age-related diseases, reported that it participated in NVIDIA’s GTC 2026 conference, a major global event for artificial intelligence and accelerated computing held from March 16 to 19, 2026.
Biophytis attended in collaboration with LynxKite Technologies and Nebius, combining its expertise in aging biology with LynxKite’s AI platform and Nebius’ AI cloud to develop AI-driven computational approaches for drug discovery in the fast-growing longevity market.
At GTC, Biophytis met with investors and industrial partners, presented its AI-driven drug discovery platform, and joined a live demonstration at the Nebius booth featuring the MAS receptor and lead candidate BIO101, illustrating how advanced GPU-based tools may help model biological targets and support discovery of new therapies for age-related diseases.
Biophytis SA completed a capital increase of €2,015,000 through new shares, pre‑funded warrants and attached warrants, and repaid all variable price convertible debt. The deal was subscribed by institutional investors including Alumni Capital for €1,250,000 and Hexagon Capital Fund for €300,000.
In total, 30,957,144 new shares, 27,397,060 pre‑funded warrants and 87,531,306 warrants were issued, at a 23.4% discount to the recent five‑day average share price. If all pre‑funded warrants and warrants are exercised, ordinary shares would rise to 206,579,284, representing potential dilution of up to 240% of current share capital.
The company also rescheduled €1,224,786.72 of residual debt with Kreos Capital, adding a three‑month moratorium from March to May 2026, followed by 30 monthly installments of €40,000 from June 2026 to July 2029. A 90‑day company standstill and similar lock‑up for key insiders were agreed.
Biophytis S.A. has amended its bond financing agreement with Hexagon Capital Fund, increasing the maximum nominal amount from €1,000,000 to €2,000,000 and extending the subscription period to December 31, 2027. This additional capacity is intended to strengthen its financial structure and extend its cash runway by four months.
As of February 26, 2026, Biophytis has drawn €650,000 and retains a bond drawing capacity of €1,350,000. Each bond bears 12% interest and is repaid in cash on a bi‑monthly schedule over twenty‑four months. In an event of default, the debt may be repaid in shares at €0.05654 per share, with an illustrative example showing that repaying €1,350,000 in shares (23,876,901 shares) would reduce a shareholder’s stake from 1.00% to 0.72% based on 60,693,791 shares outstanding as of February 25, 2026.
Biophytis SA has signed a landmark agreement to create a Hong Kong–based joint venture, Biophytis Biopharmaceutical Holding LTD, to advance its BIO101 drug for sarcopenia in Asia. A consortium of Asian partners, including Ronghui Renhe Life Technology, has committed up to US$20 million over three years, with US$10 million expected in the first year and US$3 million at the joint venture’s creation.
Biophytis and its founders will own 29% of the joint venture, while Asian partners will hold 71%, with a board including three Biophytis representatives and two from the partners. The joint venture is expected to be created within 180 days and become operational in the first half of 2026. It will support an international Phase 3 trial, SARA-31, enrolling 942 patients to seek conditional marketing authorization for BIO101 in sarcopenia in Asia and Europe, starting in the second half of 2026 after regulatory approvals in China and Japan.
Biophytis SA’s shareholder disclosure shows that BlackRock Portfolio Management LLC has filed Amendment No. 1 to a Schedule 13G regarding its position in the company’s common stock. As of 12/31/2025, BlackRock Portfolio Management LLC reports beneficial ownership of 1,905,946 shares of Biophytis common stock, representing 4.8% of the outstanding class. All of these shares are reported with sole voting and sole dispositive power, with no shared power.
The filing explains that this reflects securities beneficially owned, or deemed beneficially owned, by certain business units of BlackRock, Inc. and its subsidiaries, and excludes other disaggregated business units. It also notes that various underlying persons have rights to dividends or sale proceeds, but no single person has more than five percent of the total outstanding common shares. BlackRock Portfolio Management LLC certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Biophytis SA.
Biophytis S.A. submitted a Form 6-K as a foreign private issuer to provide investors with an English-language update about its corporate governance. The company reports that on November 13, 2025 it issued a press release announcing the results of its Combined General Meeting. That press release is included with this report as Exhibit 99.1, allowing shareholders to review the meeting outcomes in more detail.
Biophytis S.A., a foreign private issuer based in Paris, submitted a Form 6-K to provide investors with its Interim Financial Report for the first half of fiscal year 2025. The company states that this interim report, dated October 31, 2025, is attached as Exhibit 99.1 and incorporated by reference, meaning the detailed financial and operational information for the period is contained in that exhibit.
BlackRock Portfolio Management LLC filed a Schedule 13G reporting beneficial ownership of 1,215,469 shares (5.2%) of Biophytis SA common stock. The filing indicates sole voting power over 1,215,469 shares and sole dispositive power over 1,215,469 shares, with no shared voting or dispositive power.
The event date is 09/30/2025. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The CUSIP is F1022R155. Item 6 notes that Kreos Capital VI (Expert Fund) LP has an interest in more than five percent of the company’s common stock.